BACKGROUND: Management of asymptomatic early stage chronic lymphocytic leukemia
(CLL) centered on expectant surveillance for active disease warranting chemotherapy. In …

Summary Abstract Rituximab (MabThera®, Rituxan®) is an anti-CD20 monoclonal antibody
that induces lysis and apoptosis of normal and malignant human B cells, and sensitises …

Rituximab has modest activity in relapsed chronic lymphocytic leukemia (CLL)/small
lymphocytic lymphoma but is associated with tumor necrosis factor-α (TNF-α) release that …

Abstract RFC (rituximab, fludarabine, cyclophosphamide) regimen showed extraordinary
clinical activity in untreated CLL patients, with high rates of overall response (ORR) …

The introduction of targeted agents such as the monoclonal antibodies rituximab (anti-
CD20) and alemtuzumab (anti-CD52) has brought about a remarkable change in the …

Chronic lymphocytic leukemia (CLL) is a B-cell leukemia mainly affecting older adults.
Historically, CLL has been regarded as an incurable disease, and treatment has been …

Rituximab is a chimeric monoclonal antibody directed at CD20 with significant activity in non-
Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). A variety of pathways of …

This prospective non-interventional study assessed the management of relapsed/refractory
CLL after one or two treatments with rituximab, and retreatment with a rituximab-based …

The management of “slow-go” patients with chronic lymphocytic leukemia (CLL) remains a
primary unmet clinical need. This subgroup of patients, underrepresented in clinical trials …

Rituximab is the first monoclonal antibody to be approved for use by the US Food and Drug
Administration in cancer. Its role in the treatment of non-Hodgkin lymphoma, including …